BAR HARBOR – Jackson Laboratory is announcing a multimillion-dollar collaboration with pharmaceutical giant Sanofi to try to tackle two kinds of cancer.

The Bar Harbor laboratory said Thursday it has signed a research agreement for up to $4.2 million with Sanofi to identify new targets to treat triple-negative breast cancer and ovarian carcinoma. The lab describes triple-negative as the most deadly form of breast cancer, and ovarian cancer as ranking fifth in cancer deaths among women.

Jackson Laboratory professor Jacques Banchereau says the laboratory is hopeful its work will lead to a new therapy that helps patients suffering from the cancers. Jackson Laboratory says Banchereau’s lab uses unique computational algorithms to inform cancer research work.

The lab says the approach could facilitate “more targeted and effective treatments” for disease.